Menopause, HRT and oral contraceptive Flashcards
Why can’t we measure GnRH
It’s not in the peripheral circulation
What is a common symptom of menopause
Sleep Disturbance
What may be some of the patient worries regarding HRT and menopause
Bones- damaging effects of menopause on the bone (loss of bone density) Breast cancer (side effects of HRT) ‘Blood clots in the leg’ Stroke ‘Heart attack’- CVS effects of HRT
Define menopause
Permanent cessation of menstruation
Loss of ovarian follicular activity
They stop making estradiol
What are the key features of menopause
Average age 51 (range 45-55)
Climacteric: period of transition period- periods become irregular until they eventually stop.
How do some women view menopause
This is a natural process of life.
The body at the beginning will get a bit mad.
Describe the eventual transition to menopause
Climacteric period
You go from having normal regular cycles and then it becomes a little irregular (oligomenorrhoea) and then it progresses to amenorrhoea.
Permanent cessation of menstruation - amenorrhoea for more than 12 months
State the symptoms of menopause
Hot flushes (head, neck, upper chest) Urogenital atrophy & dyspareunia (pain having sexual intercourse)
Sleep disturbance
Depression
Decreased libido
Joint pain
Symptoms usually diminish/disappear with time.
What do the ovaries produce that has feedback on the HPG axis
Oestradiol and Inhibin B
Negative feedback at the level of the anterior pituitary and the hypothalamus.
Describe the hormonal changes in menopause
The ovaries no longer produce estradiol and inhibin B
Hence, less negative feedback on the anterior pituitary and the hypothalamus
High GnRH, high LH and high FSH.
Describe how oesteoporosis is a key complication of menopause
Oestrogen deficiency
Loss of bone matrix
10-fold increased risk of fracture
§ Loss of 1-3% of bone mass/year and have 10x increase risk of fracture.
Lose anabolic effects of oestrogen on bone (via osteoblasts).
Describe cardiovascular disease as a key complication of menopause
protected against CVD before the menopause
have the same risk as men by the age of 70
What is the key aim of HRT
Control vasomotor symptoms (hot flushes) - which are very problematic for paitents- major disruption to their life.
Summarise the basis of HRT that should be given to post-menopausal women
Oestrogen (E):
endometrial proliferation
risk of endometrial carcinoma
Progestogens (P)- sheds endometrial lining- thus reducing the risk of endometrial cancer
HRT: E + P to prevent endometrial hyperplasia
Describe the basis of HRT is the woman has had a hysterectomy
(If hysterectomy: E only)
No endometrium, thus no risk of endometrial cancer.
Describe two common HRT formulations
can be cyclical, with oestrogen daily and progesterone every two weeks, or continuous combined
Describe the different oestrogen preparations
Oral estradiol (1mg)
Oral conjugated equine oestrogen (0.625 mg)
Transdermal (patch) oestradiol (50 microgram/day)
Intravaginal
Describe the absorption and metabolism of estradiol
Oestradiol is absorbed well but it is heavily metabolised in the liver (first pass) so the bioavailability is very low.
This means that in oral preparations, you must give a high dose of oestradio
Describe some different preparations of estradiol
Estrone sulphate (‘conjugated’ oestrogen)
Ethinyl estradiol :a semi-synthetic oestrogen
The ethinyl group protects the molecule from first pass metabolism- core part or oral contraceptives.
What can most oestrogens be administered as
Most oestrogens can also be administered via transdermal skin patches
State some of the side effects of HRT
Breast cancer Coronary heart disease Deep Vein thrombosis Stroke Gallstones
What is the key difference between the doses of oestrogen given in HRT and the doses in oral contraceptives
In HRT you are just giving a little bit of oestrogen to prevent the symptoms of menopause.
In contraception, you are trying to suppress the HPG axis so you give a more potent type of oestrogen.
What is important to remember regarding the absolute risk of HRT complications
The absolute risk of complications for healthy symptomatic postmenopausal women in their 50s taking HRT for five years is very low.
What are the take home messages form the WHI trials
Increased risk of CHD events!
19 additional events/yr per 10,000 women
Mean age: 63 years
Timing of exposure is important
No excess risk in younger menopausal women
Women < 10 years since menopause or 50-59 years: no excess risk